MCM
CPRX

Massar Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Massar Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$381K Sell
15,382
-2,958
-16% -$70.5K 0.04% 188
2025
Q4 		$428K Buy
+18,340
New +$409K 0.05% 224

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Massar Capital Management's CPRX Position: Q1 2026 in Review

Massar Capital Management reduced its Catalyst Pharmaceutical (CPRX) stake by 16% in Q1 2026, selling an estimated $70.5K and leaving 15,382 shares worth $381K. The position accounts for 0.04% of the portfolio, ranked #188.

Massar Capital Management first reported a position in CPRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $428K in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Massar Capital Management held 15,382 shares of Catalyst Pharmaceutical worth $381K as of Q1 2026.
  • Massar Capital Management sold 2,958 Catalyst Pharmaceutical shares in Q1 2026, an estimated $70.5K.
  • Catalyst Pharmaceutical made up 0.04% of Massar Capital Management's portfolio in Q1 2026, its #188 holding.
  • Massar Capital Management first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 2 quarters since.
  • Massar Capital Management's Catalyst Pharmaceutical position peaked at $428K in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Massar Capital Management's 13F filing for Q1 2026, filed 15 May 2026.